Search Page

1

Cite

Share

Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial.

Curran A, Rull A, Navarro J, Vidal-González J, Martin-Castillo M, Burgos J, Falcó V, Ribera E, Torrella A, Planas B, Peraire J, Crespo M. Curran A, et al. J Clin Med. 2020 Apr 25;9(5):1246. doi: 10.3390/jcm9051246. J Clin Med. 2020. PMID: 32344934 Free PMC article.

Cite

Share

2

Cite

Share

Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.

Masarone M, Troisi J, Aglitti A, Torre P, Colucci A, Dallio M, Federico A, Balsano C, Persico M. Masarone M, et al. Metabolomics. 2021 Jan 16;17(2):12. doi: 10.1007/s11306-020-01756-1. Metabolomics. 2021. PMID: 33458794

Cite

Share

3

Cite

Share

Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes.

Bril F, Leeming DJ, Karsdal MA, Kalavalapalli S, Barb D, Lai J, Rabe M, Cusi K. Bril F, et al. Diabetes Care. 2019 Jul;42(7):1348-1351. doi: 10.2337/dc18-2578. Epub 2019 May 21. Diabetes Care. 2019. PMID: 31221701

Cite

Share

4

Cite

Share

Metabolic liver disease in diabetes - From mechanisms to clinical trials.

Dewidar B, Kahl S, Pafili K, Roden M. Dewidar B, et al. Metabolism. 2020 Oct;111S:154299. doi: 10.1016/j.metabol.2020.154299. Epub 2020 Jun 20. Metabolism. 2020. PMID: 32569680 Free PMC article. Review.

Cite

Share

5

Cite

Share

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

Bril F, McPhaul MJ, Caulfield MP, Castille JM, Poynard T, Soldevila-Pico C, Clark VC, Firpi-Morell RJ, Lai J, Cusi K. Bril F, et al. J Investig Med. 2019 Feb;67(2):303-311. doi: 10.1136/jim-2018-000864. Epub 2018 Oct 10. J Investig Med. 2019. PMID: 30309884 Free PMC article.

Cite

Share

6

Cite

Share

A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.

Cusi K. Cusi K. Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350. Liver Int. 2020. PMID: 32077613 Review.

Cite

Share

7

Cite

Share

Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study.

Perez-Diaz-Del-Campo N, Riezu-Boj JI, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Milagro FI, Tur JA, Abete I, Zulet MA, Martinez JA. Perez-Diaz-Del-Campo N, et al. Diagnostics (Basel). 2021 Jun 13;11(6):1083. doi: 10.3390/diagnostics11061083. Diagnostics (Basel). 2021. PMID: 34199237 Free PMC article.

Cite

Share

8

Cite

Share

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes.

Fan W, Torok NJ. Fan W, et al. Hepatol Commun. 2021 Apr 9;5(4):553-555. doi: 10.1002/hep4.1662. eCollection 2021 Apr. Hepatol Commun. 2021. PMID: 33860113 Free PMC article.

Cite

Share

9

Cite

Share

Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults.

Cantero I, Elorz M, Abete I, Marin BA, Herrero JI, Monreal JI, Benito A, Quiroga J, Martínez A, Huarte MP, Uriz-Otano JI, Tur JA, Kearney J, Martinez JA, Zulet MA. Cantero I, et al. Int J Med Sci. 2019 Jan 1;16(1):75-83. doi: 10.7150/ijms.28044. eCollection 2019. Int J Med Sci. 2019. PMID: 30662331 Free PMC article. Clinical Trial.

Cite

Share

10

Cite

Share

Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease.

Lambrecht J, Tacke F. Lambrecht J, et al. Front Immunol. 2021 Feb 9;11:634409. doi: 10.3389/fimmu.2020.634409. eCollection 2020. Front Immunol. 2021. PMID: 33633748 Free PMC article. Review.

Cite

Share